Lung cancer: 28 major events in 2020

28 major events in the field of lung cancer in 2020, lung cancer patients must know! Lung cancer is a global cancer, and the number of tumors in the world ranks second.

In the past 2020, the field of lung cancer is surging, whether it is targeted therapy or immunotherapy, new breakthroughs have been ushered in, and the treatment pattern has been very different from the past.

Today, the good doctors will take stock of important events in the field of lung cancer in 2020!

01.23 ◆ “China Treatment Guidelines for Primary Lung Cancer Stage IV (2020 Edition)” released

On January 23, 2020, the “Guidelines for the Treatment of Stage IV Primary Lung Cancer in China (2020 Edition)” were released, and the detailed medications for immunotherapy (pembrolizumab monotherapy or pembrolizumab combined with chemotherapy) were used as domestic guidelines for the first time The priority recommendation.

Aletinib is newly recommended as the first-line treatment recommendation for patients with advanced ALK fusion-positive non-small cell lung cancer; dacomitinib and osimertinib are recommended for first-line treatment of patients with advanced non-small cell lung cancer with sensitive mutations in the EGFR gene. Among them, osimertinib can also be the first-line treatment of advanced NSCLC patients with EGFRT790M gene mutation.

02.13 ◆ Atelizumab was launched in China

On February 13, 2020, the National Drug Administration (NMPA) approved atelizumab to be marketed in China, combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.

03.18 ◆ The first domestically produced third-generation EGFR targeted drug was launched

On March 18, 2020, China’s National Medical Products Administration (NMPA) approved the domestic third-generation EGFR-targeted drug Ametinib to be marketed for use in patients with advanced non-small cell lung cancer who have advanced EGFR-TKI treatment and are T790M-positive.

03.25 ◆ The world’s first oral MET inhibitor approved

On March 25, 2020, the Ministry of Health, Labour and Welfare of Japan approved Tepotinib for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer with MET-14 exon skip mutations. This is the world’s first oral MET inhibitor approved for marketing Agent.

03.30 ◆ Duvalizumab was approved for small cell lung cancer

On March 30, 2020, the U.S. Food and Drug Administration (FDA) approved duvalizumab combined with chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer.

04.28 ◆ K drug long-interval dosing regimen was approved

On April 28, 2020, the U.S. Food and Drug Administration (FDA) accelerated the approval of a new dosing regimen (400 mg once every 6 weeks) for Pembrolizumab (Drug K), which is applicable to all currently approved adaptations disease. The previous dosage regimen was 200 mg, once every 3 weeks.

05.06 ◆ The first FDA approved MET inhibitor was launched

On May 6, 2020, the FDA accelerated the approval of Capmatinib for use in patients with metastatic non-small cell lung cancer carrying MET-14 exon skipping mutations.

05.08 ◆ The world’s first specific RET inhibitor was launched

On May 8, 2020, the FDA accelerated the approval of Selpercatinib (LOXO-292) for metastatic non-small cell lung cancer patients with positive RET fusion genes, becoming the world’s first specific RET inhibitor to be marketed.

05.15 ◆ The dual immunization program was approved for the first time for lung cancer

On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved “Nivolumab + Ipilimumab” (O+Y) for the combination of PD-L1 expression ≥ 1% and EGFR or ALK negative First-line treatment for patients with metastatic non-small cell lung cancer.

05.15 ◆ The fourth edition of NCCN Guidelines updated

On May 15, 2020, the NCCN non-small cell lung cancer diagnosis and treatment guidelines were updated to the fourth edition, with new treatment recommendations for MET-14 exon jumping mutations and RET fusion mutations.

05.18 ◆ Ateliizumab single-agent first-line treatment approved

On May 18, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Atezolizumab, T drug) for the treatment of patients with metastatic non-small cell lung cancer with high PD-L1 expression and EGFR/ALK negative First-line treatment.

05.22 ◆ Brigatinib was approved for listing

On May 22, 2020, the U.S. Food and Drug Administration (FDA) approved Brigatinib for ALK-positive metastatic non-small cell lung cancer patients.

05.23 ◆ “CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2020 Edition)” released

On May 23, 2020, the new version of the CSCO guidelines was released, which updated many treatment strategies.

For the first time, pembrolizumab±chemotherapy was regarded as a grade I recommendation; at the same time, a new grade II recommendation for carrelizumab combined with chemotherapy for advanced non-squamous non-small cell lung cancer was added. Duvalizumab for consolidation therapy in stage III patients has also been upgraded to a level I recommendation.

For EGFR-positive patients, dacomitinib is newly added as the first-line treatment (level I recommendation); the first-line treatment of osimertinib is also upgraded from a level II recommendation to a level I recommendation. For T790M positive after drug resistance, new targeted drug Ametinib (level II recommendation).

For ALK-positive patients, aletinib is newly added as a level I recommendation for ALK-positive patients; brigatinib is newly added as the first-line medication for ALK-positive patients (level III recommendation).

For patients with ROS1 fusion mutations, Entrectinib is newly recommended as a first-line treatment.

New first-line recommendation for BRAF V600E mutation and NTRK fusion: For BRAF V600E mutation, patients can also choose dabrafenib ± trametinib; NTRK fusion mutation can choose larotrectinib or entretinib.

For patients who progressed after targeted therapy, the previous classification of “local progress, slow progress, and rapid progress” was changed and divided into three categories: oligoprogress, central nervous system progress, and extensive progress.

05.27 ◆ The fifth edition of NCCN Guidelines updated

On May 27, 2020, the NCCN non-small cell lung cancer diagnosis and treatment guidelines were updated to the fifth edition, adding atezizumab as a PD-L1 high expression (PD-L1 ≥50%) metastatic non-small cell lung cancer First-line treatment is recommended.

05.27 ◆ Ceritinib was approved first-line

On May 27, 2020, the National Medical Products Administration (NMPA) of China approved the ALK second-generation targeted drug Seritinib (450mg) for the first-line treatment of ALK-positive advanced non-small cell lung cancer patients.

05.29 ◆ A+T new plan was approved first-line

On May 29, 2020, the U.S. Food and Drug Administration (FDA) formally approved ramucirumumab combined with erlotinib as the first line of metastatic non-small cell lung cancer carrying EGFR19 exon deletion or 21 exon mutation treatment.

06.15 ◆ Second-line new drug for small cell lung cancer was approved

On June 15, 2020, the U.S. Food and Drug Administration (FDA) accelerated the approval of Lurbinectedin for the treatment of patients with recurrent small cell lung cancer who had disease progression after platinum-based chemotherapy.

06.17 ◆ TMB was first approved as a biomarker

On June 17, 2020, the U.S. Food and Drug Administration (FDA) accelerated the approval of Pembrolizumab’s second “cancer-free” indication for single-agent treatment of high tumor mutation burden (TMB-H) And patients with unresectable or metastatic solid tumors whose disease has progressed after previous treatments do not need to consider the type of cancer. This is the first time that TMB has been approved by the FDA as a biomarker to guide patients’ treatment options.

06.19 ◆ China’s first domestically produced PD-1 was approved for lung cancer

On June 19, 2020, China’s domestic immune PD-1 inhibitor carrelizumab was officially approved for lung cancer indications, combined with pemetrexed and carboplatin for the first-line treatment of advanced or metastatic non-squamous non-small cells Lung cancer. This is also the first Chinese-made immunity drug approved for lung cancer indications.

06.19 ◆ Chinese domestic bevacizumab analogues were approved

On June 19, 2020, the bevacizumab analogue (trade name: Dayotong) independently developed by China Cinda Biotech was officially approved by NMPA for the treatment of advanced non-small cell lung cancer and metastatic colon cancer.

07.07 ◆ Lurbinectin is recommended in NCCN guide

On July 7, 2020, NCCN small cell lung cancer diagnosis and treatment guidelines were updated to the fourth edition, adding Lurbinectin as a second-line treatment recommendation.

09.11 ◆ NCCN Guidelines updated to the seventh edition

On September 11, 2020, the NCCN Non-Small Cell Lung Cancer Diagnosis and Treatment Guidelines were updated to the seventh edition, adding Pratinib (Pralsetinib) as a priority recommendation for RET fusion mutations.

10.16 ◆ “2020 White Paper on the Quality of Life of Chinese Cancer Patients” was officially released

On October 16, 2020, under the guidance of the Science Department of the Chinese Anti-Cancer Association and the Science Committee of the Chinese Anti-Cancer Association, the “White Paper on Quality of Life for Chinese Cancer Patients 2020” co-sponsored by Mijian and “Physician Daily” was officially released.

11.19 ◆ The first Chinese-made ALK inhibitor was approved

On November 19, 2020, the National Medical Products Administration (NMPA) of China approved the first domestic ALK inhibitor, Ensatinib, for use in patients who have progressed or become intolerant to crizotinib after receiving crizotinib treatment. Patients with locally advanced or metastatic non-small cell lung cancer who are ALK-positive.

11.20 ◆ The bone metastasis drug desulumab was approved

On November 20, 2020, Disumab was approved for the prevention of bone metastases from solid tumors and bone-related events caused by multiple myeloma.

11.25 ◆ NCCN Guidelines 2021 released

On November 25, 2020, the NCCN Non-Small Cell Lung Cancer Diagnosis and Treatment Guidelines were updated to the 2021 version, and multiple updates were made to the diagnosis and treatment strategies.

For the first time, osimertinib is recommended as an adjuvant treatment for patients with stage IB-IIIA EGFR mutations. Patients who have received adjuvant chemotherapy or who are intolerant to chemotherapy can use osimertinib;

The recommended level of the Erlotinib + Bevacizumab combination regimen was raised to 2A, removing the restriction on “use in specific situations”;

Newly added Duvalizumab for non-small cell lung cancer patients who are not resectable after radiotherapy and chemotherapy (Class 2A recommendation);

For ALK-positive patients, the new guidelines will upgrade brigatinib from “other recommendation” to “priority recommendation”;

For patients with negative driver genes and high PD-L1 expression, the first-line atelizumab single-agent therapy is newly recommended as a priority;

Added “MET high-level amplification” as an emerging target.

12.19 ◆ The first adjuvant targeted therapy approved

On December 19, 2020, the US Food and Drug Administration (FDA) approved osimertinib for postoperative adjuvant treatment of non-small cell lung cancer with sensitive EGFR mutations based on the results of the ADAURA study. This is the first targeted adjuvant therapy approved by the FDA.

12.28 ◆Announcement of China’s new medical insurance catalog

On December 28, 2020, China’s new version of the medical insurance catalog was announced, and multiple blockbuster drugs were included in medical insurance. The indications for carrelizumab for lung cancer, the indications for the first-line treatment of osimertinib and cerritinib are included in the medical insurance, the indications for the third-line treatment of erlotinib for small cell lung cancer, and the indications for the second-line treatment of amitinib Included in China Medical Insurance.

(source:internet, reference only)

Disclaimer of medicaltrend.org